-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Downgrades Apogee Therapeutics to Hold, Raises Price Target to $135

Benzinga·06/24/2026 14:59:23
Listen to the news
Stifel analyst Akash Tewari downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Hold and raises the price target from $133 to $135.